131 related articles for article (PubMed ID: 12646988)
1. Plasma immunoadsorption therapy for Guillain-Barré syndrome: critical day for initiation.
Takei H; Komaba Y; Araki T; Iino Y; Katayama Y
J Nippon Med Sch; 2002 Dec; 69(6):557-63. PubMed ID: 12646988
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barré syndrome.
Okamiya S; Ogino M; Ogino Y; Irie S; Kanazawa N; Saito T; Sakai F
Ther Apher Dial; 2004 Jun; 8(3):248-53. PubMed ID: 15154879
[TBL] [Abstract][Full Text] [Related]
3. [Comparative study of the efficacy of plasma exchange, immunoadsorption plasmapheresis and corticosteroid administration in the treatment of Guillain-Barré syndrome].
Yamazaki M; Koh CS; Hanyu N; Sakai T; Inoue A; Yanagisawa N
Arerugi; 1995 Apr; 44(4):498-502. PubMed ID: 7598643
[TBL] [Abstract][Full Text] [Related]
4. [Double filtration and immunoadsorption plasmapheresis in Guillain-Barré syndrome].
Kuwabara S; Nakajima M; Moroo I; Hirayama K
Rinsho Shinkeigaku; 1996 Feb; 36(2):289-92. PubMed ID: 8752682
[TBL] [Abstract][Full Text] [Related]
5. Plasma adsorption in critical care.
Yang KS; Kenpe K; Yamaji K; Tsuda H; Hashimoto H
Ther Apher; 2002 Jun; 6(3):184-8. PubMed ID: 12109940
[TBL] [Abstract][Full Text] [Related]
6. Guillain-Barré syndrome treated by membrane plasma exchange and/or immunoadsorption.
Marn Pernat A; Buturović-Ponikvar J; Svigelj V; Ponikvar R
Ther Apher Dial; 2009 Aug; 13(4):310-3. PubMed ID: 19695065
[TBL] [Abstract][Full Text] [Related]
7. [Apheresis therapy in Guillain-Barré syndrome].
Nagayama H; Katayama Y
Nihon Rinsho; 2008 Jun; 66(6):1195-9. PubMed ID: 18540370
[TBL] [Abstract][Full Text] [Related]
8. Experience of double filtration plasmapheresis in the treatment of Guillain-Barré syndrome.
Chen WH; Yeh JH; Chiu HC
J Clin Apher; 1999; 14(3):126-9. PubMed ID: 10540367
[TBL] [Abstract][Full Text] [Related]
9. Selective immune adsorption treatment of severe Guillain Barré syndrome in the intensive care unit.
Galldiks N; Dohmen C; Neveling M; Fink GR; Haupt WF
Neurocrit Care; 2009 Dec; 11(3):317-21. PubMed ID: 19642026
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study.
Kaynar L; Altuntas F; Aydogdu I; Turgut B; Kocyigit I; Hacioglu SK; Ismailogullari S; Turgut N; Erkurt MA; Sari I; Oztekin M; Solmaz M; Eser B; Ersoy AO; Unal A; Cetin M
Transfus Apher Sci; 2008 Apr; 38(2):109-15. PubMed ID: 18331814
[TBL] [Abstract][Full Text] [Related]
11. [Plasmapheresis in Guillain-Barre syndrome].
Carbajal-Ramírez A; Castañón-González JA; Osvaldo-Talavera J; de la Torre-Nieto ML; León-Gutiérrez MA
Gac Med Mex; 2002; 138(6):527-31. PubMed ID: 12532617
[TBL] [Abstract][Full Text] [Related]
12. Can immunoadsorption plasmapheresis be used as the first choice therapy for neuroimmunological disorders?
Yamawaki T; Suzuki N
Ther Apher; 1997 Nov; 1(4):348-52. PubMed ID: 10225729
[TBL] [Abstract][Full Text] [Related]
13. Immunoadsorption therapy for a child with Guillain-Barre syndrome subsequent to Mycoplasma infection: a case study.
Arakawa H; Yuhara Y; Todokoro M; Kato M; Mochizuki H; Tokuyama K; Kunimoto F; Morikawa A
Brain Dev; 2005 Sep; 27(6):431-3. PubMed ID: 16122631
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and complication rates for double-filtration plasmapheresis in patients with Guillain-Barré syndrome.
Lin JH; Tu KH; Chang CH; Chen YC; Tian YC; Yu CC; Hung CC; Fang JT; Yang CW; Chang MY
Transfus Apher Sci; 2015 Feb; 52(1):78-83. PubMed ID: 25544386
[TBL] [Abstract][Full Text] [Related]
15. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of anti-glycolipid antibody-associated neuropathy].
Yuki N
Rinsho Shinkeigaku; 1999 Dec; 39(12):1232-4. PubMed ID: 10791085
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features of Guillain-Barré syndrome in 41 patients admitted to a public hospital].
Cea G; Jara P; Quevedo F
Rev Med Chil; 2015 Feb; 143(2):183-9. PubMed ID: 25860360
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing outcome in Guillain-Barré Syndrome: comparison of plasma adsorption against other treatments.
Seta T; Nagayama H; Katsura K; Hamamoto M; Araki T; Yokochi M; Utsumi K; Katayama Y
Clin Neurol Neurosurg; 2005 Oct; 107(6):491-6. PubMed ID: 16202823
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of therapeutic membrane plasmapheresis in the treatment of Guillain-Barré syndrome: A study from a tertiary care hospital from India.
Vikrant S; Thakur S; Sharma A; Gupta D; Sharma S
Neurol India; 2017; 65(3):527-531. PubMed ID: 28488614
[TBL] [Abstract][Full Text] [Related]
20. [Immunoadsorption therapy with TR-350 (tryptophan column) for Guillain-Barré syndrome: investigation including serum antiganglioside antibody assay].
Araki T; Nakata H; Kusunoki S; Arai Y; Katayama Y
Rinsho Shinkeigaku; 2000 Oct; 40(10):979-85. PubMed ID: 11296374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
